PMC:7544934 / 24075-24846
Annnotations
LitCovid_Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T59 | 317-320 | https://glytoucan.org/Structures/Glycans/G00057MO | denotes | LDN |
| T60 | 317-320 | https://glytoucan.org/Structures/Glycans/G31736BK | denotes | LDN |
| T61 | 451-454 | https://glytoucan.org/Structures/Glycans/G00057MO | denotes | LDN |
| T62 | 451-454 | https://glytoucan.org/Structures/Glycans/G31736BK | denotes | LDN |
| T63 | 501-504 | https://glytoucan.org/Structures/Glycans/G00057MO | denotes | LDN |
| T64 | 501-504 | https://glytoucan.org/Structures/Glycans/G31736BK | denotes | LDN |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T10 | 732-740 | Phenotype | denotes | Pruritus | http://purl.obolibrary.org/obo/HP_0000989 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 537 | 369-375 | Gene | denotes | ERK1/2 | Gene:5595 |
| 538 | 486-490 | Gene | denotes | ACE2 | Gene:59272 |
| 539 | 285-293 | Species | denotes | patients | Tax:9606 |
| 540 | 717-727 | Chemical | denotes | Naltrexone | MESH:D009271 |
| 541 | 14-22 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 542 | 75-84 | Disease | denotes | infection | MESH:D007239 |
| 543 | 88-96 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 544 | 277-284 | Disease | denotes | COVID19 | MESH:C000657245 |
| 545 | 732-762 | Disease | denotes | Pruritus in Systemic Sclerosis | MESH:D011537 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T171 | 0-214 | Sentence | denotes | As a reliable COVID-19 vaccine is unlikely to available before the maximal infection of COVID-19 has occurred, it is essential to establish therapeutics for the individuals at moderate and high risk of the disease. |
| T172 | 215-316 | Sentence | denotes | So far, anti-viral medication is a major available option for COVID19 patients (Madjid et al., 2020). |
| T173 | 317-500 | Sentence | denotes | LDN which showed properties like anti-inflammatory, ERK1/2 inhibitory, and as well virtual docking and simulation data also suggested LDN may disrupt the interaction of ACE2 with RBD. |
| T174 | 501-771 | Sentence | denotes | LDN has been gaining credibility in its ability to halt the progression of several diseases without significant side effects when administered in low dosage ( Toljan and Vrooman, 2018; Younger et al., 2014; Low-Dose Naltrexone for Pruritus in Systemic Sclerosis, XXXX ). |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32930058-32219363-56195701 | 310-314 | 32219363 | denotes | 2020 |